Acumen Pharmaceuticals (ABOS) Insider Trading & Ownership $1.36 -0.05 (-3.55%) Closing price 04:00 PM EasternExtended Trading$1.36 +0.00 (+0.37%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Acumen Pharmaceuticals (NASDAQ:ABOS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage9.30%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$233.12K Get ABOS Insider Trade Alerts Want to know when executives and insiders are buying or selling Acumen Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ABOS Insider Buying and Selling by Quarter Acumen Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/23/2025Matt ZugaCFOSell28,902$1.72$49,711.44 1/21/2025Daniel Joseph OconnellCEOSell12,619$1.59$20,064.21 1/21/2025Eric SiemersInsiderSell3,219$1.59$5,118.21 1/21/2025Matt ZugaCFOSell4,364$1.60$6,982.40 1/21/2025Russell BartonCOOSell2,914$1.61$4,691.54 1/3/2025Daniel Joseph OconnellCEOSell47,778$1.84$87,911.52 1/3/2025Eric SiemersInsiderSell10,859$1.85$20,089.15 1/3/2025Matt ZugaCFOSell13,235$1.84$24,352.40 1/3/2025Russell BartonCOOSell7,636$1.86$14,202.96 (Data available from 1/1/2013 forward) ABOS Insider Trading Activity - Frequently Asked Questions Who is on Acumen Pharmaceuticals' Insider Roster? The list of insiders at Acumen Pharmaceuticals includes Daniel Joseph Oconnell, Derek M Meisner, Eric Siemers, Jeffrey L. Ives, Matt Zuga, Ra Capital Management, L.P., and Russell Barton. Learn more on insiders at ABOS. What percentage of Acumen Pharmaceuticals stock is owned by insiders? 9.30% of Acumen Pharmaceuticals stock is owned by insiders. Learn more on ABOS's insider holdings. Which Acumen Pharmaceuticals insiders have been selling company stock? The following insiders have sold ABOS shares in the last 24 months: Daniel Joseph Oconnell ($160,719.73), Derek M Meisner ($31,086.84), Eric Siemers ($25,207.36), Matt Zuga ($96,784.06), and Russell Barton ($29,461.59). How much insider selling is happening at Acumen Pharmaceuticals? Insiders have sold a total of 162,734 Acumen Pharmaceuticals shares in the last 24 months for a total of $343,259.58 sold. Acumen Pharmaceuticals Key ExecutivesMr. Daniel J. O'Connell M.B.A. (Age 54)CEO & Director Compensation: $1.04MMr. Matt ZugaCFO & Chief Business OfficerMr. Derek M. Meisner Esq. (Age 53)J.D., Chief Legal Officer & Corporate Secretary Compensation: $752.95kDr. James Doherty Ph.D. (Age 56)President & Chief Development Officer Dr. Grant A. Krafft Ph.D.Co-FounderDr. Caleb E. Finch Ph.D.Co-FounderDr. William L. Klein Ph.D.Co-FounderMr. Russell Barton M.S. (Age 65)Chief Operating Officer Compensation: $223.68kMs. Kelly CarranzaVice President, Finance & Accounting and Corporate ControllerMs. Alex Braun M.B.A.VP & Head of Investor Relations More Insider Trading Tools from MarketBeat Related Companies Arcturus Therapeutics Insider Ownership Corvus Pharmaceuticals Insider Ownership Abeona Therapeutics Insider Ownership Olema Pharmaceuticals Insider Ownership Aldeyra Therapeutics Insider Ownership Amarin Insider Ownership Benitec Biopharma Insider Ownership Rocket Pharmaceuticals Insider Ownership Inhibrx Biosciences Insider Ownership Neurogene Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say BuyStrategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying This page (NASDAQ:ABOS) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access